Neurocrine Biosciences, Inc. (NBIX)
Market Cap | 13.84B |
Revenue (ttm) | 1.98B |
Net Income (ttm) | 369.70M |
Shares Out | 100.64M |
EPS (ttm) | 3.65 |
PE Ratio | 37.67 |
Forward PE | 29.37 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 703,849 |
Open | 138.80 |
Previous Close | 140.11 |
Day's Range | 136.92 - 139.12 |
52-Week Range | 93.28 - 148.37 |
Beta | 0.36 |
Analysts | Buy |
Price Target | 155.32 (+12.97%) |
Earnings Date | Jul 30, 2024 |
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to trea... [Read more]
Full Company ProfileFinancial Performance
In 2023, NBIX's revenue was $1.89 billion, an increase of 26.76% compared to the previous year's $1.49 billion. Earnings were $249.70 million, an increase of 61.62%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is $155.32, which is an increase of 12.97% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/c/k/press13-2504451.jpg)
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
PDUFA Target Action Dates in Late December 2024 Highly Selective CRF1 Antagonist is the Potential First New Treatment for CAH in 70 Years SAN DIEGO , July 1, 2024 /PRNewswire/ -- Neurocrine Bioscience...
![](https://cdn.snapi.dev/images/v1/e/g/press6-2458802.jpg)
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology pipeline at t...
![](https://cdn.snapi.dev/images/v1/5/w/press1-2458691.jpg)
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
- CAHtalyst™ Pediatric Study Met Primary and Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintainin...
![](https://cdn.snapi.dev/images/v1/d/w/press7-2458645.jpg)
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
- CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction Wh...
![](https://cdn.snapi.dev/images/v1/i/n/conf17-2452470.jpg)
Neurocrine Biosciences to Participate at Investor Conferences in June
Jefferies Global Healthcare Conference on June 5 in New York Goldman Sachs 45th Annual Global Healthcare Conference on June 13 in Miami SAN DIEGO, May 29, 2024 /PRNewswire/ -- Neurocrine Biosciences, ...
![](https://cdn.snapi.dev/images/v1/m/e/biotech4-2450688.jpg)
Neurocrine founder-CEO Gorman to retire in October
Neurocrine Biosciences CEO Kevin Gorman will retire on Oct. 11 after three decades with the company that he founded and will be succeeded by insider Kyle Gano.
![](https://cdn.snapi.dev/images/v1/w/g/press7-2450564.jpg)
Neurocrine Biosciences Announces CEO Succession Plan
Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D.
![](https://cdn.snapi.dev/images/v1/d/m/conf7-2449726.jpg)
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
New CAHtalyst™ Pediatric and CAHtalyst™ Adult Phase 3 Clinical Study Data in Congenital Adrenal Hyperplasia CAHtalog™ Registry Data Highlighting Impact of Supraphysiologic Glucocorticoid Dosing Phase ...
![](https://cdn.snapi.dev/images/v1/7/c/press17-2442389.jpg)
Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules
SAN DIEGO , May 21, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA® (valbe...
![](https://cdn.snapi.dev/images/v1/s/g/press11-2429300.jpg)
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults - Phase 2 Study for Modified-Release Hydrocortisone in Adults ...
![](https://cdn.snapi.dev/images/v1/j/h/press8-2421046.jpg)
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce Adrenal Androgens and Supraphysiologic Glucocorticoid Dosing in CAH Adult Patients Comprehensive Litera...
![](https://cdn.snapi.dev/images/v1/h/l/press1-2420752.jpg)
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
SAN DIEGO , May 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, ph...
![](https://cdn.snapi.dev/images/v1/n/s/press12-2420118.jpg)
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-...
![](https://cdn.snapi.dev/images/v1/i/e/press11-2417944.jpg)
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, p...
![](https://cdn.snapi.dev/images/v1/x/v/conf6-2416277.jpg)
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
SAN DIEGO , May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m.
![](https://cdn.snapi.dev/images/v1/f/x/conf4-2414603.jpg)
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal Hyperplasia Phase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone (Chronocort®/Efmody...
![](https://cdn.snapi.dev/images/v1/i/6/press6-2411870.jpg)
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and about 65% have not yet been diagnosed1-3 The diagnosis rate can be improved by increasing routine TD screenings...
![](https://cdn.snapi.dev/images/v1/g/g/press11-2409756.jpg)
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
CAHtalyst™ Pediatric Study Baseline Characteristics Data Highlight Need for Novel Treatments in Children and Adolescents with Congenital Adrenal Hyperplasia (CAH) CAHtalog™ Registry Data of Glucocorti...
![](https://cdn.snapi.dev/images/v1/w/z/press13-2402241.jpg)
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
INGREZZA® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth INGREZZA® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA Crinecerfont New Drug ...
![](https://cdn.snapi.dev/images/v1/p/q/biotech38-2401498.jpg)
FDA approves Neurocrine Biosciences' Huntington's disease drug
The U.S. Food and Drug Administration (FDA) has approved granule formulation of Neurocrine Biosciences' drug to treat movement disorders associated with Huntington's disease, the company said on Tuesd...
![](https://cdn.snapi.dev/images/v1/k/p/press5-2401455.jpg)
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
SAN DIEGO , April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a n...
![](https://cdn.snapi.dev/images/v1/o/k/press17-2387978.jpg)
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share experiences and learn about current research.
![](https://cdn.snapi.dev/images/v1/q/g/press2-2384974.jpg)
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statisti...
![](https://cdn.snapi.dev/images/v1/a/x/press12-2372793.jpg)
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
Tokyo, Japan and Cambridge, UK, 16 April 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – has been notified by its partner Neurocri...
![](https://cdn.snapi.dev/images/v1/f/6/conf10-2366148.jpg)
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 1 SAN DIEGO , April 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarte...